Brief: Ose Immunotherapeutics Will Pause Development Of OSE‑230
02/03/2026 19:12
March 2 (Reuters) - OSE Immunotherapeutics SA OSE.PA: OSE IMMUNOTHERAPEUTICS ACCELERATES STRATEGIC REFOCUSING TO ADVANCE LATE STAGE VALUE DRIVERS LUSVERTIKIMAB AND TEDOPI® OSE IMMUNOTHERAPEUTICS SA: CO WILL PAUSE DEVELOPMENT OF OSE‑230 Source text: ID:nGNX3wW5ht Further company coverage: OSE.PA
Recent news on Ose Immunotherapeutics SA
See all newsFactbox: Moderna-Merck melanoma vaccine leads race for first therapeutic cancer vaccine
Brief: OSE Immunotherapeutics SA Appoints Thomas Gidoin As Deputy CEO
Brief: Ose Immunotherapeutics Will Pause Development Of OSE‑230
Brief: OSE Immunotherapeutics Gets Second Positive IDMC Nod For Phase 3 Lung Cancer Trial
Brief: OSE Immunotherapeutics Announces Appointment Of Marc Le Bozec As Interim CEO